Search results
Washington aims to eradicate hepatitis C, and screening matters
Gannett via AOL· 4 days agoEven more encouraging, the newer combinations led to cure in 99% or more of patients. After more...
Barinthus Bio slashes headcount by 25% and refocuses pipeline
Pharmaceutical Technology via Yahoo Finance· 6 days agoBarinthus’ CEO Bill Enright said: “We believe that VTP-300 has great potential to do so as part of a...
Barinthus lays off 25% of staff, sidelines prostate cancer program to stretch out cash
FierceBiotech· 6 days agoBarinthus Biotherapeutics has used positive interim data from a pair of phase 2 trials for its ...
GSK signs AI pact with Ochre to pinpoint source of liver diseases
FierceBiotech· 7 days agoGSK and Ochre Bio will work together in a $37.5 million partnership to pinpoint the drivers of liver disease. The new partnership, announced Wednesday morning, will see GSK access Ochre’s computational ...
Post-viral arthritis: Causes, symptoms, and treatments
Medical News Today· 5 days agoViral arthritis is an uncommon form of arthritis that occurs following a viral infection. It can...
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Update
ETF DAILY NEWS· 6 days agoBarinthus Biotherapeutics plc (NASDAQ:BRNS – Get Free Report) was the recipient of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 5,800 ...
Barinthus Biotherapeutics (NASDAQ:BRNS) Price Target Cut to $3.00 by Analysts at Barclays
ETF DAILY NEWS· 5 days agoBarinthus Biotherapeutics (NASDAQ:BRNS – Free Report) had its target price decreased by Barclays from $7.00 to $3.00 in a research report report published on Thursday morning, Benzinga reports ...
Full body scans miss the mark when it comes to improving U.S. disease prevention
NPR· 18 hours agoFor now, however, tried-and-true strategies, from cancer screenings to vaccines, are the most effective way to safeguard our long-term well-being. “The old adage that an ounce of prevention ...
Vir Biotechnology (NASDAQ:VIR) Trading Down 5.5%
ETF DAILY NEWS· 3 days agoShares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) dropped 5.5% during trading on Friday . Approximately 272,073 shares traded hands during mid-day trading, a decline of 74% from ...